N-t-Boc-D-Leu-D-Leu | 863781-36-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-t-Boc-D-Leu-D-Leu
• 英文别名: (2R)-4-methyl-2-[[(2R)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoic acid
• CAS: 863781-36-6
• 化学式: C₁₇H₃₂N₂O₅
• 分子量: 344.451
• InChiKey: PBTNVAYSJPRTLQ-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-t-Boc-D-Leu-D-Leu 在 N,N-二异丙基乙胺 盐酸 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 苯甲醚 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 98.0h， 生成 cyclo[D-Leu-D-Leu-D-Val-D-Leu-D-Phe]
  参考文献：
  名称：

  Sansalvamide A衍生物的合成及其在MSS结肠癌细胞系HT-29中的细胞毒性。

  摘要：

  我们报告了36种Sansalvamide A衍生物的合成及其对结肠癌HT-29细胞系（一种微卫星稳定（MSS）结肠癌细胞系）的生物活性。这三十六种化合物可分为三个子集，其中化合物的第一子集包含L-氨基酸，第二个子集包含D-氨基酸，而第三子集包含D-和L-氨基酸。五种化合物表现出出色的抑制活性（抑制率> 75％）。化合物的结构活性关系（SAR）确定了位置2或3上的单个D-氨基酸比Sansalvamide A肽的细胞毒性提高了10倍。这项工作强调了残基2和3的重要性以及D-氨基酸在该类化合物的非常规SAR中的作用。

  DOI：

  10.1016/j.bmc.2006.04.031
• 作为产物：
  描述：

  BOC-D-亮氨酸 在 lithium hydroxide 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-t-Boc-D-Leu-D-Leu
  参考文献：
  名称：

  Sansalvamide A衍生物的合成及其在MSS结肠癌细胞系HT-29中的细胞毒性。

  摘要：

  我们报告了36种Sansalvamide A衍生物的合成及其对结肠癌HT-29细胞系（一种微卫星稳定（MSS）结肠癌细胞系）的生物活性。这三十六种化合物可分为三个子集，其中化合物的第一子集包含L-氨基酸，第二个子集包含D-氨基酸，而第三子集包含D-和L-氨基酸。五种化合物表现出出色的抑制活性（抑制率> 75％）。化合物的结构活性关系（SAR）确定了位置2或3上的单个D-氨基酸比Sansalvamide A肽的细胞毒性提高了10倍。这项工作强调了残基2和3的重要性以及D-氨基酸在该类化合物的非常规SAR中的作用。

  DOI：

  10.1016/j.bmc.2006.04.031

文献信息

• High-yielding macrocyclization conditions used in the synthesis of novel Sansalvamide A derivatives
  作者：Thomas J. Styers、Rodrigo Rodriguez、Po-Shen Pan、Shelli R. McAlpine

  DOI：10.1016/j.tetlet.2005.11.056

  日期：2006.1

  Described are the syntheses of nine Sansalvamide A derivatives using new, high-yielding, in situ deprotection–cyclization conditions that are general for this series of macrocycles, 55% average for both steps. This is 10-fold greater than previously reported yields.

  描述了使用新的，高产的，原位脱保护-环化条件合成的九种Sansalvamide A衍生物，该条件对于该系列大环化合物而言是通用的，两个步骤的平均值均为55％。这是以前报道的产量的十倍。
• Synthesis and Cytotoxicity of a New Class of Potent Decapeptide Macrocycles
  作者：Melinda R. Davis、Thomas J. Styers、Rodrigo A. Rodriguez、Po-Shen Pan、Robert C. Vasko、Shelli R. McAlpine

  DOI：10.1021/ol702403r

  日期：2008.1.1

  were made using a succinct convergent synthesis. These analogues share no structural homology to current cancer drugs, are cytotoxic at levels on par with existing drugs treating cancers, and demonstrate selectivity for drug-resistant pancreatic cancer cell lines over noncancerous cell lines. These molecules are excellent chemotherapeutic leads in the search for new anticancer agents.

  描述了五种十肽的合成，它们是天然五肽Sansalvamide A的C-2-对称衍生物。使用简洁的收敛性合成方法制得衍生物。这些类似物与目前的癌症药物没有结构同源性，在细胞毒性方面与现有的治疗癌症的药物相当，并且显示出对耐药性胰腺癌细胞系比非癌细胞系具有选择性。这些分子是寻找新的抗癌药的出色化学治疗方法。
• Synthesis and Cytotoxicity of Novel Sansalvamide A Derivatives
  作者：Chris L. Carroll、Jennifer V. C. Johnston、Ahmet Kekec、Joseph D. Brown、Emily Parry、Julia Cajica、Irene Medina、Kristina M. Cook、Ricardo Corral、Po-Shen Pan、Shelli R. McAlpine

  DOI：10.1021/ol051161g

  日期：2005.8.1

  [GRAPHICS]Described are the syntheses of 14 derivatives of the natural product Sansalvamide A, where two are more active against HCT 116 colon cancer cell lines than the natural product. These derivatives were synthesized using a combinatorial-type strategy that permits elucidation of the amino acid role in the cytotoxicity, and they lay the groundwork for development of new anticancer agents.
• Comprehensive Study of Sansalvamide A Derivatives and their Structure–Activity Relationships against Drug-Resistant Colon Cancer Cell Lines
  作者：Katerina Otrubova、Gerald Lushington、David Vander Velde、Kathleen L. McGuire、Shelli R. McAlpine

  DOI：10.1021/jm070731a

  日期：2008.2.1

  We report an extensive structure-activity relationship (SAR) of 62 compounds active against two drug-resistant colon cancer cell lines. Our comprehensive evaluation of two generations of compounds utilizes SAR, NMR, and molecular modeling to evaluate the key 3D features of potent compounds. Of the seven most potent compounds reported here, five are second-generation, emphasizing our ability to incorporate potent features found in the first generation and utilize their structures to design potency into the second generation. These analogs share no structural homology to current colon cancer drugs, are cytotoxic at levels on par with existing drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell lines over noncancerous cell lines. Thus, we have established sansalvamide A as an excellent lead for treating, multiple drug-resistant colon cancers.
• Antibody Recognition of Chiral Surfaces. Enantiomorphous Crystals of Leucine-Leucine-Tyrosine
  作者：Merav Geva、Felix Frolow、Miriam Eisenstein、Lia Addadi

  DOI：10.1021/ja027942j

  日期：2003.1.1

  Monoclonal antibodies were selected after immunization with crystals of the tripeptide L-leucine-L-leucine-L-tyrosine. They interact with the tripeptide crystals, but do not interact with the tripeptide molecule, with other crystalline surfaces, or with adsorbed protein. The interactions of two antibodies with crystals of L-Leu-L-Leu-L-Tyr and of its enantiomer D-LeU-D-Leu-D-Tyr were characterized in depth. Antibody 48E is stereoselective and enantioselective: it recognizes only the 0(1) over bar 1} faces of the L-Leu-L-Leu-L-Tyr crystals, and not the enantiomorphous 01(1) over bar} faces of D-Leu-D-Leu-D-Tyr crystals, or any other faces of either crystal. In contrast antibody 602E is poorly stereoselectiwe and is not enantioselective: it recognizes the crystals of both enantiomers, interacting With a number of different faces of each. The different recognition patterns are explained on the basis of the nature of the interactions and the structure of the interacting surfaces. Understanding this antibody specificity advances our general understanding of surface recognition and transfer of chiral information across biological interfaces.